Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Y-mAbs Therapeutics: Aktionäre stimmen auf Hauptversammlung allen Vorschlägen zu | 1 | Investing.com Deutsch | ||
Di | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.05. | Clear Street erhöht Kursziel für YMAB-Aktie auf 17 US-Dollar, Aktien steigen | 1 | Investing.com Deutsch | ||
28.05. | Clear Street raises YMAB stock target to $17, shares rise | 1 | Investing.com | ||
28.05. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline | 3 | GlobeNewswire (USA) | ||
26.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting | 2 | GlobeNewswire (USA) | ||
Y-MABS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
19.05. | What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics | 1 | Benzinga.com | ||
19.05. | H.C. Wainwright cuts YMAB stock target to $11, maintains Buy rating | 1 | Investing.com | ||
13.05. | Y-mAbs Therapeutics outlines Q2 revenue guidance of $17M-$19M amid DANYELZA NCCN guideline inclusion and expanded ex-U.S. growth | 1 | Seeking Alpha | ||
13.05. | Y-mAbs Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
13.05. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 | 1 | GlobeNewswire (USA) | ||
13.05. | Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook | 3 | Seeking Alpha | ||
13.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments | 285 | GlobeNewswire (Europe) | Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines... ► Artikel lesen | |
12.05. | Preview: Y-mAbs Therapeutics' Earnings | 1 | Benzinga.com | ||
07.05. | Y-mAbs gets NCCN recommendation for neuroblastoma treatment | 2 | Seeking Alpha | ||
07.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA) | 160 | GlobeNewswire (Europe) | PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and... ► Artikel lesen | |
06.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 | 2 | GlobeNewswire (USA) | ||
27.04. | Y-mAbs Therapeutics, Inc.: Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting | 130 | GlobeNewswire (Europe) | NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,55 | -0,10 % | BioNTech-Konkurrent Moderna: Aktie mit Kurssprung - was ist da los? | Die Aktie von Moderna hat am Dienstag einen kräftigen Kurssprung hinlegen können. Das Papier ging als Top-Gewinner des Tages im S&P 500 vor Intel und Albemarle aus dem Handel. Moderna notiert nun so... ► Artikel lesen | |
EVOTEC | 7,286 | -0,22 % | Aktienmarkt: Evotec-Aktie tritt auf der Stelle (7,232 €) | Im deutschen Wertpapierhandel ist das Wertpapier von Evotec aktuell unauffällig. Der jüngste Kurs betrug 7,23 Euro. Wenig getan hat sich heute bislang beim Kurs von Evotec. Mit einem Preis von 7,23... ► Artikel lesen | |
CUREVAC | 4,694 | +0,21 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
MODERNA | 26,995 | -1,62 % | Moderna's latest approval again reveals FDA rift over COVID vaccines | ||
NOVAVAX | 5,967 | -0,18 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
HEIDELBERG PHARMA | 4,670 | -1,48 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma berichtet über das erste Halbjahr 2025 und positiven Geschäftsverlauf | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Halbjahresbericht
Heidelberg Pharma berichtet über das erste Halbjahr 2025 und positiven Geschäftsverlauf
10.07.2025 / 07:03... ► Artikel lesen | |
CRISPR THERAPEUTICS | 47,600 | +0,42 % | Cathie Wood's ARK buys CRSP stock, sells ROKU and MASS | ||
INOVIO PHARMACEUTICALS | 1,120 | -2,61 % | Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug | ||
INTELLIA THERAPEUTICS | 10,435 | +1,46 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
EDITAS MEDICINE | 2,380 | -2,34 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
DYNAVAX | 8,768 | -1,51 % | Dynavax Technologies: Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum | Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return
Urges... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 15,635 | -1,11 % | JPMorgan senkt Kursziel für Sarepta Therapeutics auf 28 US-Dollar | ||
BIOMARIN PHARMACEUTICAL | 48,290 | -3,80 % | BioMarin: Wolfe Research bestätigt Outperform-Rating trotz neuer Konkurrenz im PKU-Markt |